NCT03239561View on ClinicalTrials.gov

Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Alzheimer Disease
Interventions
DRUG

[18F]MNI-1020

Participants will receive a single intravenous bolus injection of \[18F\]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.

Trial Locations (1)

06510

Invicro, New Haven

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants | Biotech Hunter | Biotech Hunter